About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

3-D Cultures Grown from Patients' Tumors may Help Personalize Drug Screening

by Vishnuprasad on May 12, 2015 at 11:29 PM
Font : A-A+

3-D Cultures Grown from Patients' Tumors may Help Personalize Drug Screening

Three-dimensional cultures derived from the tumors of cancer patients closely replicate properties of the original tumors, reveals a new study.

According to the scientists at Wellcome Trust Sanger Institute, UK, these 'organoids' are amenable to large-scale drug screens for the detection of genetic changes associated with drug sensitivity.

Advertisement

The drug screening can pave the way for personalized treatment approaches that could optimize clinical outcomes in cancer patients. "This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors. We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments," says Mathew Garnett, a geneticist at the Institute.

In the new study, the scientists grew 22 organoids from 20 patients with colorectal cancer and then sequenced genomic DNA isolated from these cultures.
Advertisement

The genetic mutations in the cultures closely matched those in the corresponding tumor biopsies and agreed well with previous large-scale analyses of colorectal cancer mutations. These findings confirm that the cultures faithfully capture the genomic features of the tumors from which they are derived as well as much of the genomic diversity associated with colorectal cancer.

The scientist screened the responses of the organoids to 83 cancer drugs. Given their diverse genetic profiles, the organoids displayed a range of sensitivities to the drugs.

The researchers identified previously reported associations between specific mutations and resistance to particular drugs. The organoids also showed a novel gene-drug association, indicating that the subset of cancer patients with RNF43 mutations would strongly benefit from a drug that inhibits a protein called porcupine.

"At some point in the future, this approach may be suitable for modeling individual patient response to cancer therapies to inform clinical treatment," Garnett says. The study was published in the Cell.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ways to Manage Stress during COVID-19 Pandemic
Can Adjusting Fatty Acid Intake Improve Mood in Bipolar Disorder Patients?
Insulin Resistance Doubles the Risk of Major Depressive Disorder
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity 

Recommended Reading
Pre-Cancerous Lesions
Encyclopedia section of medindia gives general information about Pre Cancerous Lesions...
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use